Gilead drug reduces chest pain episodes in diabetics: study

by admin on March 10, 2013

SAN FRANCISCO (Reuters) – Gilead Sciences Inc's angina drug Ranexa reduced incidents of chest pain in patients with diabetes, and the effect appeared to be more pronounced in those with poor blood sugar control, according to data from a clinical trial. Ranexa, known chemically as ranolazine, is already approved to treat angina – a type of chest pain associated with heart disease. This was the …

View full post on pain – Yahoo! News Search Results

Previous post:

Next post: